Brief Research Report

Published on 07 Oct 2024

Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d)

in Vaccines and Molecular Therapeutics

Goh Ohji
Yohei Funakoshi
Kimikazu Yakushijin
Takaji Matsutani
Tomoki Sasaki
Takahiro Kusakabe
Sakuya Matsumoto
Taiji Koyama
Yoshiaki Nagatani
Keiji Kurata

Frontiers in Immunology

doi 10.3389/fimmu.2024.1468760

Original Research

Accepted on 04 Oct 2024

Comparison of Antibody Responses of Heterologous and Homologous Covid-19 Booster Vaccination: An Observational Study

in Vaccines and Molecular Therapeutics

Nayab Batool Rizvi
Maryam Bibi
Muhmmad Zeeshan Rana
Sehrish Zaffar
Hassam Farooq

Frontiers in Immunology

doi 10.3389/fimmu.2024.1448408

1,096 views

Original Research

Accepted on 03 Oct 2024

Development and characterization of high-throughput serological assays to measure magnitude and functional immune response against S. Paratyphi A in human samples

in Vaccines and Molecular Therapeutics

Martina Carducci
Luisa Massai
Elisa Lari
Bianca Semplici
Silvia Grappi
Noshi Maria
Elizabeth Jones
Valentino Conti
Pietro Piu
Francesco Berlanda Scorza

Frontiers in Immunology

doi 10.3389/fimmu.2024.1443137

Systematic Review

Published on 03 Oct 2024

DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies

in Vaccines and Molecular Therapeutics

Alisa Kazakova
Pavel Zhelnov
Roman Sidorov
Anna Rogova
Olga Vasileva
Roman Ivanov
Vasiliy Reshetnikov
Albert Muslimov

Frontiers in Immunology

doi 10.3389/fimmu.2024.1457327

290 views

Review

Published on 03 Oct 2024

Towards personalized vaccines

in Vaccines and Molecular Therapeutics

Davide Montin
Veronica Santilli
Alessandra Beni
Giorgio Costagliola
Baldassarre Martire
Maria Felicia Mastrototaro
Giorgio Ottaviano
Caterina Rizzo
Mayla Sgrulletti
Michele Miraglia Del Giudice

Frontiers in Immunology

doi 10.3389/fimmu.2024.1436108

104 views

Review

Accepted on 02 Oct 2024

Mycobacterium w -a promising immunotherapeutic intervention for diseases

in Vaccines and Molecular Therapeutics

Kirsten Stefan
Ryan Gordon
Annah Rolig
Alexander Honkala
Dhanir Tailor
Lara E. Davis
Rajiv I Modi
Manjul Joshipura
Bakulesh Khamar
Sanjay V Malhotra

Frontiers in Immunology

doi 10.3389/fimmu.2024.1450118

Original Research

Published on 02 Oct 2024

M protein ectodomain-specific immunity restrains SARS-CoV-2 variants replication

in Vaccines and Molecular Therapeutics

Yibo Tang
Kaiming Tang
Yunqi Hu
Zi-Wei Ye
Wanyu Luo
Cuiting Luo
Hehe Cao
Ran Wang
Xinyu Yue
Dejian Liu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1450114

204 views

Correction

Published on 02 Oct 2024

Corrigendum: MAVS disruption impairs downstream signaling and results in higher virus replication levels of salmonid alphavirus subtype 3 but not infectious pancreatic necrosis virus in vitro

in Vaccines and Molecular Therapeutics

Cheng Xu
Amr A. A. Gamil
Xiaolin Wang
Hetron Mweemba Munang’andu
Øystein Evensen

Frontiers in Immunology

doi 10.3389/fimmu.2024.1500204

Original Research

Published on 01 Oct 2024

Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy

in Vaccines and Molecular Therapeutics

Colton Ladbury
Claire Hao
William Tyler Watkins
Sagus Sampath
Jeffrey Wong
Arya Amini
Karen Sokolov
Jekwon Yeh
Karine A. Al Feghali
Dorine de Jong

Frontiers in Immunology

doi 10.3389/fimmu.2024.1419788

103 views

Original Research

Published on 01 Oct 2024

Nanospheres as the delivery vehicle: novel application of Toxoplasma gondii ribosomal protein S2 in PLGA and chitosan nanospheres against acute toxoplasmosis

in Vaccines and Molecular Therapeutics

WeiYu Qi
YouLi Yu
ChenChen Yang
XiaoJuan Wang
YuChen Jiang
Li Zhang
ZhengQing Yu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1475280

172 views

Review

Published on 01 Oct 2024

Future applications of host direct therapies for infectious disease treatment

in Vaccines and Molecular Therapeutics

Ruth E. Thom
R V. D’Elia

Frontiers in Immunology

doi 10.3389/fimmu.2024.1436557

248 views

Original Research

Accepted on 30 Sep 2024

Coxiella burnetii Nine Mile phase I primary infection derived protective immunity against C. burnetii reinfection in mice depends on both B and T cells, but T cells play a critical role

in Vaccines and Molecular Therapeutics

Muhammad Shawkat Alam
Venkatesh Kumaresan
Rajesh Palanisamy
Yan Zhang
Janakiram Seshu
Na Xiong Xiong
Guoquan Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1427822

Review

Published on 30 Sep 2024

Integrating machine learning to advance epitope mapping

in Vaccines and Molecular Therapeutics

Simranjit Grewal
Nidhi Hegde
Stephanie K. Yanow

Frontiers in Immunology

doi 10.3389/fimmu.2024.1463931

283 views

Original Research

Accepted on 25 Sep 2024

Induction of Neutralizing Antibody Responses by AAV5-based Vaccine for Respiratory Syncytial Virus in Mice

in Vaccines and Molecular Therapeutics

Gangyuan Ma
Zeping Xu #
Chinyu Li
Feng Zhou
Bobo Hu
Junwei Guo
Changwen Ke
Liqing Chen
Guilin Zhang
Hungyan Lau

Frontiers in Immunology

doi 10.3389/fimmu.2024.1451433

Correction

Published on 25 Sep 2024

Corrigendum: Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV

in Vaccines and Molecular Therapeutics

Shi Zou
Wei Guo
Songjie Wu
Fangzhao Ming
Yuting Tan
Mengmeng Wu
Weiming Tang
Ke Liang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1494940

104 views

Original Research

Accepted on 24 Sep 2024

High Prevalence of Long COVID in Anti-TPO Positive Euthyroid Individuals with Strongly Elevated SARS-CoV-2-Specific T Cell Responses and Moderately Raised Anti-Spike IgG Levels 23 Months Post-InfectionStrongly Elevated Anti-TPO Antibodies and SARS-CoV-2-Specific T Cell Responses, with Moderately Raised Anti-Spike IgG Levels in Long COVID Patients 23 Months Post-Infection

in Vaccines and Molecular Therapeutics

Zsolt Matula
Viktória Király
Gabriella Bekő
Márton Gönczi
András Zóka
Róbert Steinhauser
Ferenc Uher
István Vályi-Nagy

Frontiers in Immunology

doi 10.3389/fimmu.2024.1448659

Navigation group

Articles

Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d)

Comparison of Antibody Responses of Heterologous and Homologous Covid-19 Booster Vaccination: An Observational Study

Development and characterization of high-throughput serological assays to measure magnitude and functional immune response against S. Paratyphi A in human samples

DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies

Towards personalized vaccines

Mycobacterium w -a promising immunotherapeutic intervention for diseases

M protein ectodomain-specific immunity restrains SARS-CoV-2 variants replication

Corrigendum: MAVS disruption impairs downstream signaling and results in higher virus replication levels of salmonid alphavirus subtype 3 but not infectious pancreatic necrosis virus in vitro

Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy

Nanospheres as the delivery vehicle: novel application of Toxoplasma gondii ribosomal protein S2 in PLGA and chitosan nanospheres against acute toxoplasmosis

Future applications of host direct therapies for infectious disease treatment

Coxiella burnetii Nine Mile phase I primary infection derived protective immunity against C. burnetii reinfection in mice depends on both B and T cells, but T cells play a critical role

Integrating machine learning to advance epitope mapping

Induction of Neutralizing Antibody Responses by AAV5-based Vaccine for Respiratory Syncytial Virus in Mice

Corrigendum: Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV